Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05395104 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants

A Phase 1 study of Healthy Volunteers, sponsored by Shionogi.

Completed
Registry status
Phase 1
Development phase
14
Enrollment target
1
Study location

NCT05395104: Completed Phase 1 study of Healthy Volunteers, sponsored by Shionogi.

NCT05395104 is a Phase 1 study of Healthy Volunteers that has completed, run by Shionogi. The registered enrollment target is 14 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05395104, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Shionogi.

COMPLETED
Registry status
Phase 1
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effect of repeated doses of cefiderocol on the PK of midazolam.

Primary Outcome

This outcome measure presents the effects of repeated doses of cefiderocol on the pharmacokinetics of midazolam. Cmax is reported as nanograms/milliliter (ng/mL). Day -1 is defined as Baseline.

Conditions Studied

Interventions

  • DRUG Midazolam
  • DRUG Cefiderocol

Study Locations (1)

Texas

  • Worldwide Clinical Trials - San Antonio

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2022-05-24
Est. Completion 2022-07-13
Phase Phase 1
Shionogi

54 total trials

What the finished NCT05395104 record still lists

NCT05395104 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 2 interventions - of which Midazolam is the first listed.

NCT05395104 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05395104 about?

NCT05395104 is a clinical study titled "A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants". The purpose of this study is to determine the effect of repeated doses of cefiderocol on the PK of midazolam.

What is the current status of trial NCT05395104?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2022-05-24. Estimated completion is 2022-07-13.

What conditions does trial NCT05395104 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT05395104?

The interventions under investigation include: Midazolam (DRUG), Cefiderocol (DRUG).

Who is sponsoring clinical trial NCT05395104?

This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05395104 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05395104's enrollment target sits among peer trials

14 245th of 283 higher than 35 of 283 other Healthy Volunteers trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT05395104, the US trial registry maintained by the National Library of Medicine. NCT05395104 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.